Category: Latest News
-
Flowers Foods to Eliminate Chief Growth Officer Position
Flowers Foods Inc. (NYSE:FLO) announced that Terry Thomas will step down from his role as chief growth officer, with the company also confirming that the position will be discontinued. The role was introduced in 2023 as part of an effort to strengthen the company’s growth strategy and develop new capabilities. Thomas will remain with the…
-
Bargain Hunting May Spark Early Rebound on Wall Street: Dow Jones, S&P, Nasdaq, Futures
U.S. stock futures are pointing to a higher open on Monday, suggesting equities may recover some of the ground lost during last week’s sharp sell-off. Early gains could be driven by bargain hunting, as some investors take advantage of lower valuations following the recent market weakness. The downturn last week pushed the major U.S. indices…
-
Vertical Aerospace shares jump after announcing $800M funding package
Shares of Vertical Aerospace Ltd. (NYSE:EVTL) climbed about 16% on Monday after the company revealed plans for a financing package that could total up to $800 million. The company said on March 30, 2026, that it had reached an agreement in principle for the funding arrangement, which includes three financing components provided by two investment…
-
Viridian shares plunge despite positive Phase 3 trial results
Shares of Viridian Therapeutics (NASDAQ:VRDN) dropped about 40% on Monday after the company released topline data from its Phase 3 REVEAL-1 study of elegrobart in patients with active thyroid eye disease, even though the treatment met its primary endpoint. The trial produced a highly statistically significant treatment effect. Patients receiving elegrobart every four weeks (Q4W)…
-
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip
Neumora Therapeutics, Inc. (NASDAQ:NMRA) on Monday reported fourth-quarter results that came in ahead of analyst estimates. Despite the earnings beat, the company’s stock declined about 2.15% in premarket trading as investors assessed its cash position and ongoing pipeline developments. The clinical-stage biopharmaceutical company posted a quarterly loss of $0.35 per share, outperforming the analyst consensus…
-
Connect Biopharma shares jump after encouraging clinical data
Shares of Connect Biopharma Holdings Limited (NASDAQ:CNTB) climbed about 11% after the company released positive findings from several clinical studies evaluating rademikibart, its anti-interleukin-4-receptor alpha antibody. The company reported preliminary results from a Phase 1 clinical pharmacology trial showing that a single 300 mg intravenous dose of rademikibart, delivered via a two-minute IV push, produced…
-
Anavex withdraws EU approval filing for Alzheimer’s therapy
Anavex Life Sciences Corp. (NASDAQ:AVXL) has withdrawn its application seeking marketing authorization in the European Union for blarcamesine as a treatment for early-stage Alzheimer’s disease, the company said. The biopharmaceutical group noted that discussions with the European Medicines Agency are ongoing as it works to address issues raised by the Committee for Medicinal Products for…
-
Roma Green Finance shares jump after $100M buyback authorization
Shares of Roma Green Finance (NASDAQ:ROMA) soared about 35% after the company unveiled plans for a $100 million share repurchase program. The ESG and sustainability advisory firm said its board of directors approved the buyback initiative, which will run through December 31, 2028. Roma Green Finance currently has a market capitalization of roughly $375 million.…
-
United Therapeutics shares jump after positive results from Tyvaso trial
Shares of United Therapeutics Corporation (NASDAQ:UTHR) climbed about 12% on Monday after the company reported that its pivotal TETON-1 study of Tyvaso successfully achieved its primary endpoint in patients with idiopathic pulmonary fibrosis (IPF). The inhaled therapy demonstrated clear superiority over placebo in improving absolute forced vital capacity, showing a treatment difference of 130.1 mL.…
-
Avis Budget shares slide after company unveils equity distribution plan
Shares of Avis Budget Group (NASDAQ:CAR) dropped about 10% on Monday after the company disclosed that it had entered into an Equity Distribution Agreement with a group of major investment banks. Under the agreement, dated March 27, 2026, Avis Budget has the option to sell up to 5,000,000 shares of its common stock through a…